Zorbtive

Zorbtive is a brand name of somatropin, approved by the FDA in the following formulation(s):

ZORBTIVE (somatropin recombinant - injectable; injection)

• 
  Manufacturer: EMD SERONO
  
  Approval date: December 1, 2003
  
  Strength(s): 8.8MG/VIAL ^[RLD]

Has a generic version of Zorbtive been approved?

No. There is currently no therapeutically equivalent version of Zorbtive available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zorbtive. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method for enhancing gut absorption
  Patent 5,288,703
  Issued: February 22, 1994
  Inventor(s): Wilmore; Douglas
  Assignee(s): Brigham and Women's Hospital
  The present invention provides a method for enhancing the gut absorption in a mammal. Specifically, gut absorption in a mammal can be enhanced by the administration of glutamine, or glutamine equivalent, in combination with one or more agents, said agents selected from the group consisting of growth hormone (GH), an agent capable of enhancing endogenous GH production, insulin like growth factor 1 (IGF-1), or an agent capable of enhancing endogenous IGF-1 production.
  
  Patent expiration dates:
  
  
  • October 7, 2011
    
    ✓ 
    Patent use: USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME
  
  



• 
  hGH containing pharmaceutical compositions
  Patent 5,898,030
  Issued: April 27, 1999
  Inventor(s): Samaritani; Fabrizio
  Assignee(s): Applied Research Systems Ars Holding N.V
  Pharmaceutical compositions containing hGH stabilized by means of saccharose. The formulation is particularly suitable for stabilizing a lyophilisate of recombinant hGH.
  
  Patent expiration dates:
  
  
  • April 27, 2016
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 1, 2010 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Zorbtive Consumer Information (Drugs.com)
• Zorbtive Consumer Information (Wolters Kluwer)
• Zorbtive Consumer Information (Cerner Multum)
• Zorbtive Advanced Consumer Information (Micromedex)
• Somatropin (rDNA origin - Nonrefrigerated) Consumer Information (Wolters Kluwer)
• Somatropin (rDNA origin - Refrigerated) Consumer Information (Wolters Kluwer)
• Somatropin (rDNA origin - Refrigerated) Cartridge Consumer Information (Wolters Kluwer)
• Somatropin (rDNA origin - Refrigerated) Vial Consumer Information (Wolters Kluwer)
• Somatropin (rDNA origin - Refrigerated) Vials Consumer Information (Wolters Kluwer)
• Somatropin Consumer Information (Cerner Multum)
• Somatropin, e-coli derived Subcutaneous, Injection Advanced Consumer Information (Micromedex)
• Somatropin, mammalian derived Subcutaneous, Injection Advanced Consumer Information (Micromedex)